Adhering to the spirit of corporate social responsibility (CSR), Bio-Check proactively participates in preventive health care services. The company collaborated with gynecologists across Taiwan to start the first HPV epidemiological study in the year 2000. After five consecutive years of clinical follow-up, the results were published in international scientific journals in 2008, receiving wide-spread attention and recognition.

In 2008, Bio-Check worked together with health bureaus of local county and city governments to conduct a large pilot project on HPV self-sampling. Subsequently in 2010 the company was authorized by the Health Promotion Administration of the Ministry of Health and Welfare of the Executive Yuan to expand this cervical cancer screening program with HPV DNA testing, which became the largest-scale HPV self-sampling project in the world.

With its experience and long-term operation in the women’s health market, Bio-Check profoundly recognizes the importance and uniqueness of women’s healthcare. Therefore, the Women’s Healthcare Department was set up in 2004 to actively bring in women’s healthcare programs that meet clinical needs and prospects. From regular daily care to special cancer-related screening, today Bio-Check provides complete health protection to women of all ages.

FeatureServices

The ThinPrep Pap Smear Test

FDA certified, high-quality ThinPrep PAP Test is the best choice for cervical cancer primary screening.

Non-invasive Prenatal Screening (NIPS)

• Test as early as the 10th gestational week.
• The whole procedure is completed, and the test results are analyzed in hospital laboratories in a medical center or at the same level.

HPV DNA Test

Qiagen 13-type HPV DNA test detects high-risk HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 61 in cervical cancer cell samples.

22-type HPV DNA Test

22-type HPV DNA test distinguishes the 18 high-risk HPV type 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82, from 4 low-risk HPV type 6, 11, 70, and 81.

CT/GC rRNA test

The Aptima Combo®
2 Assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of rRNA from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal urogenital disease.

HPV mRNA Test

Hologic HPV mRNA amplification test detects specifically for E6 and E7 oncogene variations in 14 high-risk HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68

QuikCheck fFN Test

The Hologic QuikCheck fFN test is used for preterm delivery risk assessment.

NovaSure Impedance Controlled Endometrial Ablation System

NovaSure endometrial ablation procedure is a simple, safe and effective way to reduce or stop menstrual bleeding for women with abnormal uterine bleeding, proven with 15 years of demonstrated clinical performance and over 2.5 million patients treated.